LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...

A patient was found to have suffered an “unnecessary delay” in treatment for their heart condition before their death. The ...

This year's game had an extra layer of emotion that brought the Panthers together. Assistant coach Hoa Nguyen is in a current ...

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

As previously reported, Wolfe Research analyst Andy Chen upgraded Intellia Therapeutics (NTLA) to Outperform from Peer Perform with a $21 price ...

The global pharmaceutical industry could generate about $1.2 trillion in sales in 2025, according to Statista, and projections call for 4.7% annual growth through 2029. The cancer treatment ...

When Rosaline Callaghan hit her early 50s, she feared she was a ticking timebomb and it was only a matter of years before she ...

ABB announced today that it will launch a process to propose to its Annual General Meeting 2026 to decide on a 100 percent spin-off of its Robotics division.

For one, microglia hovering around plaques—the type that express the most TREM2—reportedly become desensitized to stimulation ...

Unger was able to nip calcium transients in the bud by injecting a “puff” of sTREM2 into the mouse brain with a pipette; this temporarily silenced nearby neurons, and it did so in wild-type or TREM2 ...

Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...